Aurobindo Pharma US Deal: FTC Clears $250m Buy (2026)

A key US expansion step for Aurobindo

Aurobindo Pharma has moved closer to expanding its footprint in the United States after receiving antitrust clearance from the US Federal Trade Commission (FTC) for its acquisition of Lannett Company. The Hyderabad-based generic drugmaker told Indian stock exchanges that the FTC clearance removes the final major regulatory hurdle for the transaction. The deal is valued at USD 250 million and is expected to close before the end of June, subject to completing remaining administrative steps. The development matters because it would add US manufacturing capacity and deepen Aurobindo’s product presence in a competitive market where scale, compliance, and portfolio breadth are critical.

What the FTC cleared and what it required

The FTC said it is requiring Aurobindo Pharma Limited to divest four different generic drug products in order to complete the USD 250 million acquisition of Lannett Company Inc. The regulator’s rationale was that the combination would bring together two of a limited number of competitors for four specific generic medicines, and that the deal could otherwise raise competition concerns in those product markets. The FTC framed the action as protecting American patients from higher drug costs by preserving competition. This means Aurobindo can proceed, but only after meeting the conditions laid out in the proposed consent order.

Four products to be divested to Quagen Pharmaceuticals

Under the FTC’s proposed consent order, Aurobindo must divest four generic pharmaceutical products to Quagen Pharmaceuticals LLC, which the FTC described as an experienced generic pharmaceutical company. The products listed by the FTC include:

• An immunosuppressant prescribed to prevent organ transplant rejection
• A cholesterol management drug
• A drug prescribed to treat dry mouth in radiation therapy patients
• A drug prescribed to reduce stomach acid

The divestment condition reduces the immediate size of the portfolio that changes hands under the transaction, but it also addresses the key antitrust issue raised by the regulator.

Transition services and monitoring requirements

The FTC’s proposed consent order also specifies that Aurobindo and Lannett must provide transition services so that Quagen can effectively operate the divested assets immediately. The order further provides for a monitor to oversee compliance obligations. These provisions are designed to ensure continuity of supply and operational readiness for the products that are carved out, while also ensuring the divestiture is executed in a way that maintains competition in the affected markets.

Public comment window and current case status

The FTC said the Commission vote to issue the complaint and accept the consent agreement for public comment was 2-0. The public will have 30 days to submit comments on the proposed consent agreement package, with instructions available on the docket and processed comments posted on Regulations.gov. The case status was described as “Pending” in the material referenced. While the FTC has stated the condition for proceeding, the formal process still includes the public comment period as part of the consent agreement framework.

Aurobindo’s disclosure to Indian stock exchanges

In its regulatory disclosure to Indian stock exchanges, Aurobindo said that with the FTC nod now in hand, it expects to complete remaining administrative formalities and finalize the transaction shortly. The company stated: “We anticipate that the transaction will close before the end of this month and will keep the exchanges informed if any future developments in this matter.” The update indicates the company views the regulatory step as the last major gating item and is preparing for closing actions.

What Lannett brings: products and manufacturing capacity

The acquisition of Lannett is positioned as a strategic move to expand Aurobindo’s US manufacturing base and product portfolio. Lannett is described as bringing approximately 70 products, including ADHD treatments and controlled substances. It also includes a 425,000 sq. ft. cGMP facility in Seymour, Indiana, which has been cited as having substantial scale-up potential. These elements are central to why the deal is being watched, since US-based manufacturing and controlled substance capabilities can be difficult to build organically.

Regulatory momentum: USFDA VAI classifications cited as supportive

Separate from the acquisition, Aurobindo’s stock has been described as supported by recent US regulatory outcomes. The company’s Unit V, an API manufacturing facility, received a US Food and Drug Administration (USFDA) “Voluntary Action Indicated” (VAI) classification, indicating the inspection was closed and noted deficiencies did not require significant regulatory action. Another facility, Unit-IV in Andhra Pradesh, also received a VAI classification on March 12, 2026, after inspectors issued five observations, which also closed that inspection. The article context notes that VAI outcomes have historically acted as catalysts for Aurobindo’s stock, including a similar event in December 2023 that preceded a 52-week high.

Key facts at a glance

Market impact and why investors are tracking the conditions

The immediate market implication is that Aurobindo’s path to closing is clearer, but it comes with an explicit divestment package and compliance requirements that need execution. The FTC’s condition is focused on protecting competition in four generic product markets, so investors will typically watch how smoothly the divestiture and transition services are implemented. The context also notes that some investors have expressed concern about how such conditions could affect profitability and timelines, although the company’s exchange filing indicates it still expects closing by the end of the month. Separately, the VAI classifications for Aurobindo facilities matter for market access and operational continuity, and they often influence sentiment around execution capability in the US.

Conclusion

Aurobindo Pharma has secured FTC antitrust clearance for its USD 250 million acquisition of Lannett, but must divest four generic products to Quagen and comply with transition and monitoring requirements. The company has guided for a closing before the end of June after completing remaining administrative formalities. The next near-term milestones include executing the divestitures under the consent order process and navigating the FTC’s public comment window as the case remains listed as pending.